Mefloquine and an Acute Brain Syndrome

Letters and Corrections1 April 1989Mefloquine and an Acute Brain SyndromeB. Rouveix, MD, PhD, F. Bricaire, MD, C Michon, MD, G. Franssen, BS, J Lebras, PharmD, Hôpital C. Bernard, J. Bernard, MD, F. Ajana, MD, J. L. Vienne, MDB. Rouveix, MD, PhD, F. Bricaire, MD, C Michon, MD, G. Franssen, BS, J Lebras, PharmD, Hôpital C. Bernard, J. Bernard, MD, F. Ajana, MD, J. L. Vienne, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-110-7-577 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Mefloquine, a quinolinemethanol derivative with a long half-life, is an effective therapy for chloroquine-resistant falciparum malaria and a relatively effective therapy for acute malaria. Three cases of confusion from severe acute toxicity have been reported, although they are not well documented (1, 2). We report five cases of an acute brain syndrome after mefloquine therapy in patients who returned from Africa (three patients from Gabon, one from Cameroon, and one from the Ivory Coast).Four men, aged 19, 20, 22, and 55 years, respectively, and one girl, aged 5 years, had an acute brain syndrome. None had...References1. Harinasuta T, Bunnag D, and Wersdorfer W. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull WHO. 1983;61:299-305. MedlineGoogle Scholar2. Harinasuta T, Lasserre R, BuLeviernnag D, Leimer R, and Vinijanont S. Trials of mefloquine in vivo and of mefloquine plus fansidar in falciparum malaria. Lancet. 1985;1:885-8. CrossrefMedlineGoogle Scholar3. Arnold P and Stetten O. HPLC analysis of mefloquine and its main metabolite by direct plasma injection with pre-column enrichment and column switching techniques. J Chromatogr. 1986;353:193-200. CrossrefMedlineGoogle Scholar4. Schwartz D, Eckert G, and Hartman D. Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. Chemotherapy. 1982;28:701-184. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: B. Rouveix, MD, PhD; F. Bricaire, MD; C Michon, MD; G. Franssen, BS; J Lebras, PharmD; Hôpital C. Bernard; J. Bernard, MD; F. Ajana, MD; J. L. Vienne, MDAffiliations: Produits Roche 92521 Neuilly Sur Seine Cédex, France PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIdentification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System DataAdverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patientsMalaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence ForceHow inhibition influences seizure propagationMass administration of the antimalarial drug mefloquine to Guantánamo detainees: a critical analysisLimbic encephalopathy and central vestibulopathy caused by mefloquine: A case reportStereoselective Passage of Mefloquine Through the Blood-Brain Barrier in the RatMefloquine neurotoxicity: A literature reviewReversible hearing loss in temporal association with chemoprophylactic mefloquine useKeeping Score on Psychiatric Drug Effects: Is Mefloquine Safe for Malaria Chemoprophylaxis?Psychotropic Medications and CrimeConduite pratique du traitement d'une forme non compliquée de paludisme à Plasmodium falciparumNeuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective studySevere Adverse Reaction to Prophylactic Use of Mefloquine in Nonimmune Travelers in Hoima District, UgandaSide effects of mefloquine prophylaxis for malaria: an independent randomized controlled trialNatural ProductsPost-malaria neurological syndromeMefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subjectMefloquine Prophylaxis and Hearing, Postural Control, and Vestibular FunctionsMalaria: Plasmodium falciparum (Welch 1898), Plasmodium vivax (Grassi and Filetti 1889), Plasmodium ovale (Stephens 1922), Plasmodium malariae (Laveran 1881)Neuropsychiatric side effects of mefloquine in AfricansMefloquine or doxycycline prophylaxis in US troops in SomaliaPlasmodia of HumansEncéphalopathie et troubles mnésiques au cours des traitements par la méfloquineParesthesias and Mefloquine ProphylaxisPatrick E. Olson, MD, Charles A. Kennedy, MD, Paul D. Morte, MDMalaria therapy in 452 patients, with special reference to the use of quinineProphylaxis for malariaMefloquine-sulphadoxine-pyrimethamine (Fansimef®, Roche) in the prophylaxis of Plasmodium falciparum malaria: a double-blind, comparative, placebo-controlled studyA prospective clinical trial of the treatment of falciparum malaria with mefloquine, with special reference to neuro-psychiatric side effectsSeizures after MefloquineKanwar Singh, MD, G. Dennis Shanks, MD, Henry Wilde, MDEffect of ampicillin on mefloquine pharmacokinetics in thai malesAgranulocytosis during treatment with mefloquineNutzen-Risiko-Abwägung bei Antiinfektiva aus der Sicht der ZulassungsbehördeAntiprotozoal drugsClinical efficacy of mefloquine in children suffering from chloroquine-resistant Plasmodium falciparum malaria in NigeriaEmporiatrics: Protecting Travelers from MalariaMefloguine prophylaxisMalaria prophylaxis in travellers to tropical AfricaNeurologic Reactions after a Therapeutic Dose of MefloquineEfficacy of a 3-day oral regimen of a quinine-quinidine-cinchonine association (Quinimax®) for treatment of falciparum malaria in MadagascarDivided-dose kinetics of mefloquine in man. 1 April 1989Volume 110, Issue 7 Page: 577-578 Keywords Brain Half life Malaria Mefloquine Toxicity ePublished: 1 December 2008 Issue Published: 1 April 1989 PDF downloadLoading ...